Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2023
- HDP-101 clinical trial in Europe and US continues with adjusted protocol and larger number of study sites in Europe; fifth patient cohort initiated at 100 µg/kg dosing
- Patient from third cohort continues to be dosed and shows stable disease
- Divestment of minority stake in Emergence leads to higher other income and additional cash inflows
- Sales and other income above plan, other financials in line with plan
Heidelberg Pharma AG reported today on its course of business as well as on the Group’s financial figures for the first nine months of fiscal year 2023 (1 December 2022 – 31 August 2023).